Information Provided By: 
Fly News Breaks for September 28, 2015
VSTM
Sep 28, 2015 | 12:15 EDT
UBS downgraded Verastem to Neutral and cut its price target on shares to $2.
News For VSTM From the Last 2 Days
VSTM
Apr 18, 2024 | 16:05 EDT
Verastem Oncology "announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company's clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company. Dr. Hayslip has more than 25 years of oncology and research and development experience across industry and academia, most recently serving as the chief medical officer at I-MAB Biopharma. "
